RCS - Gelion PLC - Expanded Li-S R&D Facility launched

GelionAnnouncement

11/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231011:nRSK7632Pa&default-theme=true

RNS Number : 7632P  Gelion PLC  11 October 2023

REACH

11 October 2023

Gelion plc

("Gelion" or the "Company" or the "Group")

 

Expanded Li-S R&D Facility launched to enable prototyping toward
commercial cell development

 

 

Gelion (AIM: GELN), the Anglo-Australian battery innovator, announces new
Lithium-Sulfur (Li-S) Research and Development (R&D) Facility designed to
optimise development and accelerate market readiness of this technology by
producing more advanced cell prototypes.

 

Based in Sydney, adjacent to Gelion's research and corporate office, the
facility will allow the Company to advance prototyping toward cell development
and to capitalise on the combination of Gelion's existing technologies with
the intellectual property (IP) packages acquired from Johnson Matthey in March
2023.

 

Having achieved technical progress with sulfur cathode chemistry, this
facility will enable Gelion to build multi-layer pouch cells (a soft battery
design where battery components are enclosed in a pouch casing, like in a
mobile phone or laptop), which are the industry standard for testing batteries
and the form factor used for customer off-take.

The new facility is another milestone as Gelion continues to deliver against
its go-to-market strategy and will bring a multitude of benefits to the Group,
including:

 ·         enabling researchers to more rapidly test promising research in multi-layer
           pouch cells;
 ·         enabling Gelion to effectively participate in joint development agreements
           with anode developers; and
 ·         enable the production of prototypes that can be supplied for preliminary
           third-party validation and safety testing.

 

The prototypes produced will be multi-layer pouch cells and further focused
product development ahead of offtake with partners. The prototypes will also
inform TRL 4 (Technology Readiness Levels) and are a key commercial proof
point for Gelion's technology. The facility and its output will help underpin
the winning of contracts and subsequent scale up to commercial manufacture.

 

Commenting on the new facility, John Wood, CEO said:

 

"The site has the capability to increase Gelion's prototyping toward cell
development and the progressive commissioning of the capability
commenced in late September 2023. The opening of this facility further
evidences the steady progress Gelion is making on its path to
commercialisation. We are incredibly excited to be opening this research and
development facility to increase capacity to ensure we optimise development of
Lithium Sulfur for the rapidly expanding market.

 

"Lithium-Sulfur is the next generation for electric mobility and has the
potential to power the future of transport. Gelion has built a large IP moat,
and, with its highly skilled team of specialists, we are working towards our
goal of delivering commercially viable and scalable, next generation battery
chemistries."

 

 

 

 

 

 

CONTACTS

 

 Gelion plc                                                               via Alma PR

 John Wood, CEO

 Amit Gupta, CFO

 Thomas Maschmeyer, Founder and Principal Technology Advisor

 Cavendish Capital Markets Limited  (Nominated Adviser and Sole Broker)   +44 207 220 0500
 Corporate Finance

 Neil McDonald

 Seamus Fricker

 Fergus Sullivan

 ECM

 Barney Hayward

 Alma PR (Financial PR Adviser)                                           +44 20 3405 0205

 Justine James                                                            gelion@almapr.co.uk

 Hannah Campbell

 Will Ellis Hancock

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGUBDGRXBDGXB